Insider trading

Period: 120 months Stock: PBYI + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

263 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

263 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

263 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

263 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
263 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
263 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

263 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
2 Oct 2019
BRYCE RICHARD PAUL SEE REMARKS
Sold, plan not stated
$914.55 91 at 10.05
0.2%
12 Sep 2019
HUNT DOUGLAS M See Remarks
Sold, plan not stated
$19.54K 1,711 at 11.42
11.9%
4 Sep 2019
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$5.31K 524 at 10.14
0.0%
4 Sep 2019
BRYCE RICHARD PAUL SEE REMARKS
Sold, plan not stated
$960.45 95 at 10.11
0.3%
2 Aug 2019
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated 2×
$4.67K 517 at 9.03
0.0%
2 Aug 2019
BRYCE RICHARD PAUL SEE REMARKS
Sold, plan not stated
$846.00 94 at 9.00
0.3%
22 Jul 2019
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$126.85K 12,715 at 9.98
0.3%
22 Jul 2019
Lo Steven Chief Commercial Officer
Sold, plan not stated
$18.60K 1,852 at 10.04
8.7%
22 Jul 2019
BRYCE RICHARD PAUL SEE REMARKS
Sold, plan not stated
$18.59K 1,841 at 10.10
4.8%
2 Jul 2019
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$6.33K 495 at 12.78
0.0%
2 Jul 2019
BRYCE RICHARD PAUL SEE REMARKS
Sold, plan not stated
$1.14K 89 at 12.78
0.2%
3 Jun 2019
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$7.33K 483 at 15.18
0.0%
3 Jun 2019
BRYCE RICHARD PAUL SEE REMARKS
Sold, plan not stated
$1.33K 88 at 15.07
0.2%
2 May 2019
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$15.45K 477 at 32.38
0.0%
2 May 2019
BRYCE RICHARD PAUL SEE REMARKS
Sold, plan not stated
$2.75K 85 at 32.38
0.2%
2 Apr 2019
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$17.57K 491 at 35.79
0.0%
2 Apr 2019
BRYCE RICHARD PAUL SEE REMARKS
Sold, plan not stated
$3.15K 88 at 35.78
0.2%
4 Mar 2019
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$19.16K 496 at 38.62
0.0%
4 Mar 2019
BRYCE RICHARD PAUL SEE REMARKS
Sold, plan not stated
$3.40K 88 at 38.66
0.2%
4 Feb 2019
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$9.59K 345 at 27.80
0.0%
4 Feb 2019
BRYCE RICHARD PAUL SEE REMARKS
Sold, plan not stated
$2.47K 89 at 27.77
0.3%
4 Feb 2019
EYLER CHARLES R SEE REMARKS
Sold, plan not stated
$2.40K 87 at 27.64
0.3%
22 Jan 2019
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$218.33K 8,825 at 24.74
0.2%
22 Jan 2019
Lo Steven Chief Commercial Officer
Sold, plan not stated
$52.66K 2,114 at 24.91
9.0%
22 Jan 2019
BRYCE RICHARD PAUL SEE REMARKS
Sold, plan not stated
$48.43K 1,959 at 24.72
6.3%
22 Jan 2019
EYLER CHARLES R SEE REMARKS
Sold, plan not stated
$17.68K 713 at 24.80
2.2%
3 Jan 2019
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$91.44K 4,424 at 20.67
0.1%
3 Jan 2019
EYLER CHARLES R SEE REMARKS
Sold, plan not stated
$25.01K 1,210 at 20.67
3.6%
3 Jan 2019
BRYCE RICHARD PAUL SEE REMARKS
Sold, plan not stated
$25.01K 1,210 at 20.67
3.7%
3 Dec 2018
EYLER CHARLES R SEE REMARKS
Sold, plan not stated
$28.21K 1,239 at 22.77
3.5%
20 Jul 2018
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$651.02K 12,520 at 52.00
0.3%
20 Jul 2018
BRYCE RICHARD PAUL SEE REMARKS
Sold, plan not stated
$95.38K 1,836 at 51.95
5.3%
20 Jul 2018
Lo Steven Chief Commercial Officer
Sold, plan not stated
$95.36K 1,839 at 51.85
7.3%
20 Jul 2018
EYLER CHARLES R SEE REMARKS
Sold, plan not stated
$31.69K 610 at 51.95
1.7%
1 Jun 2018
EYLER CHARLES R SEE REMARKS
Sold, plan not stated
$64.18K 1,211 at 53.00
3.3%
22 Jan 2018
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$991.68K 10,692 at 92.75
0.3%
22 Jan 2018
Lo Steven Chief Commercial Officer
Sold, plan not stated
$172.52K 1,858 at 92.85
6.8%
22 Jan 2018
BRYCE RICHARD PAUL SR VP, CLINICAL RESEARCH & DEV
Sold, plan not stated
$172.52K 1,860 at 92.75
6.8%
22 Jan 2018
EYLER CHARLES R SEE REMARKS
Bought
$62.12K 669 at 92.85
2.4%
First buy on file
1 Dec 2017
EYLER CHARLES R SEE REMARKS
Sold, plan not stated
$139.42K 1,322 at 105.46
4.4%
29 Sep 2017
BRYCE RICHARD PAUL SR VP, CLINICAL RESEARCH & DEV
Sold, plan not stated
$1.80M 15,000 at 120.00
35.5%
7 Sep 2017
BRYCE RICHARD PAUL SR VP, CLINICAL RESEARCH & DEV
Sold, plan not stated
$1.40M 14,000 at 100.10
33.9%
6 Sep 2017
BRYCE RICHARD PAUL SR VP, CLINICAL RESEARCH & DEV
Sold, plan not stated
$100.00K 1,000 at 100.00
3.5%
20 Jul 2017
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated 2×
$1.25M 13,175 at 94.73
0.3%
20 Jul 2017
Lo Steven Chief Commercial Officer
Sold, plan not stated
$188.85K 1,990 at 94.90
6.8%
20 Jul 2017
BRYCE RICHARD PAUL SR VP, CLINICAL RESEARCH & DEV
Sold, plan not stated 2×
$188.78K 1,998 at 94.48
6.8%
20 Jul 2017
EYLER CHARLES R SEE REMARKS
Sold, plan not stated
$62.99K 662 at 95.15
2.2%
3 Jul 2017
BRYCE RICHARD PAUL SR VP, CLINICAL RESEARCH & DEV
Sold, plan not stated
$435.50K 5,000 at 87.10
14.6%
12 Jun 2017
ADAGE CAPITAL PARTNERS GP, L.L.C. 10% owner · indirect
Sold, plan not stated 2×
$7.05M 88,944 at 79.31
2.3%
9 Jun 2017
ADAGE CAPITAL PARTNERS GP, L.L.C. 10% owner · indirect
Sold, plan not stated 2×
$4.71M 58,316 at 80.77
1.5%
Showing 201–250 of 263. ← Newer Page 5 of 6 Older →